JPH10504534A - 放射性標識アネキシン−ガラクトース結合体 - Google Patents
放射性標識アネキシン−ガラクトース結合体Info
- Publication number
- JPH10504534A JPH10504534A JP8502468A JP50246896A JPH10504534A JP H10504534 A JPH10504534 A JP H10504534A JP 8502468 A JP8502468 A JP 8502468A JP 50246896 A JP50246896 A JP 50246896A JP H10504534 A JPH10504534 A JP H10504534A
- Authority
- JP
- Japan
- Prior art keywords
- annexin
- galactose
- radiolabeled
- conjugate
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.診断用画像化剤によって放射性標識するためのアネキシン含有結合体であっ て、 アネキシン、 1個以上のガラクトース残基、および アネキシンと結合しているN2S2キレート を含むことを特徴とする、アネキシン含有結合体。 2.前記アネキシンがアネキシンVであることを特徴とする、請求項1に記載の アネキシン含有結合体。 3.次式: (式中のnは1以上の数を示す)で表されることを特徴とする、請求項1に記載 のアネキシン含有結合体。 4.nが1〜約5個のガラクトース残基の数を示すことを特徴とする、請求項1 に記載のアネキシン含有結合体。 5.血管血栓を画像化するための放射性標識アネキシン−ガラクトースであって 、 アネキシン; 1個以上のガラクトース残基; アネキシンと結合しているN2S2キレート;および 該キレートによって錯体化されている診断用放射性核種 を含むことを特徴とする、放射性標識アネキシン−ガラクトース。 6.前記アネキシンがアネキシンVであることを特徴とする、請求項5に記載の 放射性標識アネキシン−ガラクトース。 7.次式: (式中のnは1以上の数を示し、そしてMは放射性核種を示す)で表されること を特徴とする、請求項5に記載の放射性標識アネキシン−ガラクトース。 8.放射性核種がTc−99m、Re−186、Re−188、Pd−100、 Bi−212、Pb−212、Pd−109およびCu−67からなる群から選 択される核種であることを特徴とする、請求項5に記載の放射性標識アネキシン −ガラクトース。 9.前記放射性核種がTc−99mであることを特徴とする、請求項5に記載の 放射性標識アネキシン−ガラクトース。 10.nが1〜約5個のガラクトース残基の数を示すことを特徴とする、請求項 5に記載の放射性標識アネキシン−ガラクトース。 11.前記放射性標識アネキシン−ガラクトースの結合活性が本来のアネキシン の結合活性より20%以上大きいことを特徴とする、請求項5に記載の放射性標 識アネキシン−ガラクトース。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26106494A | 1994-06-16 | 1994-06-16 | |
US08/261,064 | 1994-06-16 | ||
PCT/US1995/000953 WO1995019791A1 (en) | 1994-01-24 | 1995-01-23 | Radiolabeled annexins |
PCT/US1995/007599 WO1995034315A1 (en) | 1994-06-16 | 1995-06-13 | Radiolabeled annexin-galactose conjugates |
US95/00953 | 1995-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10504534A true JPH10504534A (ja) | 1998-05-06 |
Family
ID=26789477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8502468A Ceased JPH10504534A (ja) | 1994-06-16 | 1995-06-13 | 放射性標識アネキシン−ガラクトース結合体 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0765166B1 (ja) |
JP (1) | JPH10504534A (ja) |
WO (1) | WO1995034315A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE237366T1 (de) * | 1994-01-24 | 2003-05-15 | Neorx Corp | Radioaktiv-markierte annexine |
US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
JPH10512852A (ja) * | 1994-12-07 | 1998-12-08 | ネオルクス コーポレイション | 放射性標識化アネキシン−ガラクトースクラスター複合体 |
CA2206274C (en) * | 1994-12-07 | 2009-06-30 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
US5804158A (en) * | 1995-05-31 | 1998-09-08 | Resolution Pharmaceuticals Inc. | Sequestered imaging agents |
AU754577B2 (en) | 1997-04-30 | 2002-11-21 | Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
IL123429A0 (en) | 1998-02-24 | 1998-09-24 | Nst Neurosurvival Technologies | Peptides and pharmaceutical compositions comprising same |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
WO2000002587A1 (en) | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
ES2533255T3 (es) | 1998-07-13 | 2015-04-08 | Board Of Regents, The University Of Texas System | Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer |
IL131266A0 (en) | 1999-08-05 | 2001-01-28 | N S T Neurosurvival Technologi | Peptides and pharmaceutical compositions comprising same |
IL125908A (en) | 1998-08-24 | 2005-05-17 | Nst Neurosurvival Technologies | Peptides and pharmaceutical compositions comprising same |
WO2000010673A1 (en) * | 1998-08-24 | 2000-03-02 | Nst Neurosurvival Technologies Ltd. | Apparatus and method for capturing particles with surface exposure of anionic phospholipids from biological fluids |
US7049140B1 (en) | 1999-04-29 | 2006-05-23 | Vanderbilt University | X-ray guided drug delivery |
US6323313B1 (en) | 1999-06-01 | 2001-11-27 | The University Of Washington | Annexin derivative with endogenous chelation sites |
US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
DE60219611T2 (de) | 2001-02-21 | 2007-12-27 | Alavita Pharmaceuticals, Inc., Mountain View | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose |
US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
JP2004529922A (ja) * | 2001-04-03 | 2004-09-30 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 生体内における細胞死の画像化の方法 |
EP1372740A2 (en) | 2001-04-03 | 2004-01-02 | Theseus Imaging Corporation | Methods for using annexin for detecting cell death in vivo and treating associated conditions |
US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
US6982154B2 (en) | 2002-02-21 | 2006-01-03 | Surromed, Inc. | Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
WO2013019730A1 (en) | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
EP3172222A4 (en) | 2014-07-24 | 2018-03-21 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
WO2018148595A1 (en) | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61225163A (ja) * | 1985-01-14 | 1986-10-06 | ネオルツクス | 放射性核種金属キレ−ト |
JPS63170400A (ja) * | 1986-12-30 | 1988-07-14 | Nippon Mejifuijitsukusu Kk | 放射性医薬品とその調製用高分子化合物 |
JPS6419058A (en) * | 1987-03-26 | 1989-01-23 | Neorx Corp | Protein labeled with radioactive nuclide |
JPH05502877A (ja) * | 1989-12-27 | 1993-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗凝血剤の診断薬としての使用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897255A (en) * | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
DE3937607A1 (de) * | 1989-11-11 | 1991-05-16 | Boehringer Ingelheim Int | Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen |
US5627036A (en) * | 1989-12-27 | 1997-05-06 | Boehringer Ingelheim International Gmbh | Use of an anticoagulant as a diagnostic agent |
US5552525A (en) * | 1991-02-08 | 1996-09-03 | Diatech Inc. | Technetium-99m labeled peptides for imaging inflammation |
JPH05508664A (ja) * | 1991-05-09 | 1993-12-02 | ボード・オブ・リージェンツ・オブ・ザ・ユニヴァーシティ・オブ・ワシントン | リン脂質標的血栓溶解剤 |
US5371184A (en) * | 1992-02-05 | 1994-12-06 | Mallinckrodt Medical, Inc. | Radiolabelled peptide compounds |
US5380646A (en) * | 1992-10-19 | 1995-01-10 | Temple University Of The Commonwealth System Of Higher Education | Thrombus detection using radiolabelled disintegrins |
-
1995
- 1995-06-13 EP EP95923885A patent/EP0765166B1/en not_active Expired - Lifetime
- 1995-06-13 JP JP8502468A patent/JPH10504534A/ja not_active Ceased
- 1995-06-13 WO PCT/US1995/007599 patent/WO1995034315A1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61225163A (ja) * | 1985-01-14 | 1986-10-06 | ネオルツクス | 放射性核種金属キレ−ト |
JPS63170400A (ja) * | 1986-12-30 | 1988-07-14 | Nippon Mejifuijitsukusu Kk | 放射性医薬品とその調製用高分子化合物 |
JPS6419058A (en) * | 1987-03-26 | 1989-01-23 | Neorx Corp | Protein labeled with radioactive nuclide |
JPH05502877A (ja) * | 1989-12-27 | 1993-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗凝血剤の診断薬としての使用 |
Also Published As
Publication number | Publication date |
---|---|
WO1995034315A1 (en) | 1995-12-21 |
EP0765166A1 (en) | 1997-04-02 |
EP0765166A4 (en) | 1998-08-19 |
EP0765166B1 (en) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10504534A (ja) | 放射性標識アネキシン−ガラクトース結合体 | |
DE69728046T2 (de) | Radioaktiv markierte annexine | |
JP3853354B2 (ja) | 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤 | |
JP2774378B2 (ja) | 映像用テクネチウム−99m標識化ポリペプチド | |
WO1998052618A1 (en) | Radiolabeled thrombus imaging agents | |
DE69533366T2 (de) | Radioaktivmarkierte annexin-galaktose-cluster konjugate | |
CA2180555C (en) | Radiolabeled annexins | |
US7115248B2 (en) | Radiolabeled annexins | |
US6099822A (en) | Imaging methods and compositions | |
JP2006515612A (ja) | 感染及び炎症の造影用強化シンチグラフィーイメージング剤 | |
WO2020238800A1 (zh) | 用于肿瘤的靶向放射性药物及其在影像指导下的靶向放射治疗与免疫治疗的联合疗法 | |
CA2185349C (en) | Radiolabeled annexin-galactose conjugates | |
JPH10512852A (ja) | 放射性標識化アネキシン−ガラクトースクラスター複合体 | |
Nicodemus et al. | In vivo Leukocytes Labeling Using a Platelet Factor 4–Derived Heparin Binding Peptide Technetium Complex | |
CA2348617A1 (en) | Imaging with tc-99m labeled fibrin-alpha-chain peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040720 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040901 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041018 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20050307 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050412 |